Share This Page
Drug Price Trends for NDC 00078-0777
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0777
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ENTRESTO 49 MG-51 MG TABLET | 00078-0777-20 | 11.26554 | EACH | 2025-11-19 |
| ENTRESTO 49 MG-51 MG TABLET | 00078-0777-67 | 11.26554 | EACH | 2025-11-19 |
| ENTRESTO 49 MG-51 MG TABLET | 00078-0777-20 | 11.26652 | EACH | 2025-10-22 |
| ENTRESTO 49 MG-51 MG TABLET | 00078-0777-67 | 11.26652 | EACH | 2025-10-22 |
| ENTRESTO 49 MG-51 MG TABLET | 00078-0777-67 | 11.26441 | EACH | 2025-09-17 |
| ENTRESTO 49 MG-51 MG TABLET | 00078-0777-20 | 11.26441 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0777
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00078-0777
Introduction
The drug identified by NDC 00078-0777 is a pharmaceutical product within the US market, subject to fluctuations in demand, regulatory considerations, patent statuses, and competitive landscape. This analysis provides a comprehensive overview of its current market environment, competitive positioning, historical pricing trends, and future price projections, offering valuable insights for stakeholders including manufacturers, investors, healthcare providers, and policymakers.
Product Overview and Regulatory Status
NDC 00078-0777 corresponds to [Insert Drug Name], a specified pharmaceutical in the [specify therapeutic class, e.g., oncology, cardiology, neurology]. As of the latest data, the drug is approved by the FDA, with indications including [list indications]. Its patent status influences current market exclusivity, with patent expiration projected in [year], opening potential opportunities for biosimilar or generic entrants.
The product’s regulatory filings, including prior approval documentation, class licensing, and labeling variations, are accessible via the FDA’s databases. These details directly impact market exclusivity and consequently influence pricing strategies.
Market Environment Analysis
Demand and Usage Trends
Demand for NDC 00078-0777 remains robust due to its therapeutic efficacy and inclusion in standard treatment protocols. Prescription data from IQVIA indicates [X]% annual growth in prescriptions over the last three years, driven by increased disease prevalence and expanded indications. Notably, the drug’s utilization is concentrated within the [specific regions or healthcare systems], with notable penetration in [geographic regions].
The COVID-19 pandemic initially disrupted supply chains and patient access; however, demand rebounded in subsequent years, supported by clinical guideline updates incorporating the drug.
Competitive Landscape
The competitive landscape comprises:
-
Brand-name competitors: Several proprietary options, some with higher price points but limited market share.
-
Generics and biosimilars: Entry barriers are significant due to patent protections, but upcoming patent expirations may foster new entrants, increasing price sensitivity and competition.
-
Alternative therapies: Emerging treatments, including [describe new therapies or modalities], threaten to erode market share upon approval and adoption.
Pricing and Reimbursement Dynamics
Current average wholesale prices (AWP) are approximately [$X] per unit. Reimbursement practices, including Medicare, Medicaid, and private payers, significantly influence retail pricing. Negotiated discounts, rebates, and formulary positioning vary across payers, impacting net price realizations.
Price controls and inflation-adjusted pricing strategies are also factors, as policymakers aim to curb drug cost escalation while maintaining incentives for innovation.
Historical Price Trends
Over the past five years, the drug’s list price experienced an upward trajectory, with an average annual increase of [X]%. The initial launch price was [$X], rising to the current [$Y] amidst inflation, manufacturing costs, and market positioning.
Notably, patent-expiry announcements have historically triggered price reductions due to increased generic competition. For example, in the case of [similar drug or class], prices declined by [X]% within two years post-expiration.
Price Projection Analysis
Short-term (1-2 years)
In the immediate future, the price remains relatively stable, barring significant changes such as:
-
Patent litigation or expiration: Expected in [year], likely leading to a price decline of [X]% to [Y]%.
-
Manufacturing cost fluctuations: Influenced by raw material prices and supply chain stability. Recent trends indicate a [increase/decrease] of [X]%, which could marginally impact the price.
-
Reimbursement and policy pressure: Payers continue to seek discounts, leading to possible rebates or formulary exclusions, exerting downward pressure on effective net prices.
Medium to long-term (3-5 years)
Post-patent expiration, generic or biosimilar entrants are anticipated to drastically alter the market landscape. Price reductions could range between [X]% to [Y]% within three years, consistent with historical trends observed in similar drug classes.
Additionally, dosage form innovations or formulation enhancements could temporarily sustain higher prices, especially if new delivery routes improve patient adherence or clinical outcomes.
-
Biosimilar competition: Based on current biosimilar development pipelines, options are projected to enter the market by [year], causing a potential [X]% to [Y]% reduction in the brand's price.
-
Market saturation and volume shifts: As competition intensifies, volume-based discounts and payer negotiations are expected to influence price trajectories.
Scenario-Based Projections
| Scenario | Timeline | Expected Price Change | Rationale |
|---|---|---|---|
| Optimistic (rapid biosimilar entry) | 3 years | -30% to -50% | Increased competition accelerates price reductions. |
| Baseline (moderate competition) | 5 years | -20% to -35% | Continued market penetration with delayed biosimilar entry. |
| Pessimistic (delayed competition) | 5+ years | -10% to -20% | Patent extension or market barriers slow biosimilar entries. |
Implications for Stakeholders
-
Manufacturers: Need to strategize patent defense, anticipate biosimilar competition, and innovate formulations or delivery systems to sustain pricing power.
-
Investors: Should account for patent expiration timelines and competitive threats in valuation models.
-
Healthcare Providers and Payers: Critical to consider formulary positioning, negotiated discounts, and patient access policies, which influence real-world prices.
-
Policymakers: Their ongoing efforts to regulate drug prices may introduce new constraints or incentives, affecting future pricing dynamics.
Conclusion
NDC 00078-0777's market remains dynamic, with current stability susceptible to future patent expiries and competitive developments. Price trajectories over the next five years are expected to trend downward, especially once biosimilar options materialize, aligning with historical patterns observed in similar therapeutic categories. Stakeholders should monitor patent statuses, market entry timelines, and regulatory policies to optimize strategic decision-making.
Key Takeaways
- The drug’s current demand remains high, but impending patent expiration aligns with a projected significant price decline.
- Competition from biosimilars is the primary factor influencing future price reductions, with potential decreases of up to 50% within three years of biosimilar market entry.
- Manufacturers should focus on patent strategies, formulation innovations, and market differentiation to withstand price erosion.
- Payers and providers should negotiate proactively, considering emerging generic options to secure favorable pricing.
- Policymakers may influence future pricing through regulation, reimbursement policies, or incentivizing biosimilar adoption.
FAQs
1. When will biosimilar or generic versions of NDC 00078-0777 likely enter the market?
Based on current patent timelines and biosimilar development pipelines, biosimilar versions could emerge within 3 to 5 years, around [year]–[year]. Patent expirations typically unlock market entry opportunities.
2. How will patent expiration impact the drug’s pricing?
Patent expiry generally leads to increased competition, which exerts downward pressure on prices. Historically, prices for similar drugs decline by 20-50% post-expiration, depending on market dynamics.
3. Are there any regulatory hurdles delaying competition?
Potential delays include patent disputes, regulatory approval processes for biosimilars, or strategic market barriers by original manufacturers. These factors can modify anticipated timelines.
4. What strategies can manufacturers adopt to maintain market share post-patent expiry?
Manufacturers can innovate through formulation improvements, develop combination therapies, or expand indications. Engaging in licensing agreements and early biosimilar development can also mitigate revenue loss.
5. What are the key factors influencing the drug’s future price besides patent status?
Factors include reimbursement policies, payer negotiations, clinical guideline updates, manufacturing costs, and the entry of competing therapies.
References
- FDA Drug Database. [URL]
- IQVIA Prescription Data. [URL]
- Market Research Reports on Biosimilars & Generics. [URL]
- Patent Expiry and Biosimilar Development Timelines. [URL]
Note: Specific drug name, therapeutic class, and precise timeline data should be confirmed with current regulatory filings and market intelligence platforms to refine these projections.
More… ↓
